Search
Golimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationaltreatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe … In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy.
Products: Solution for Injection in Pre-filled Syringe 100 mg/1.0 ml, SİMPONİ 50 MG/0,5 ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR ,3 ENJEKTÖRAntihemophilic factor, human recombinant
go.drugbank.com/drugs/DB00025ApprovedInvestigationalHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
International brands: Monarc-MMixtures: FANHDI® 1500 U.I., FANHDI 500 U.I.Insulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalInsulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening
Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, NOVOMIX 30 FLEXPEN INJECTION 100 u/mlCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersPalivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalSynagis is a composite of human (95%) and murine (5%) antibody sequences. … Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0).
Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodyProducts: SYNAGIS®100 MG SOLUCION PARA INYECCIÓN, SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON,1 ADETGlyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigational[A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120] … Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II.
Synonyms: 1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylureaMixtures: SIL - NORBORAL ® 5 MG / 1000 MG, SIL-NORBORAL ® 5/500 MGAnakinra
go.drugbank.com/drugs/DB00026ApprovedInvestigationalAnakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. … A few studies have evaluated the use of anakinra for the treatment of coronavirus disease 2019 (COVID-19).
Synonyms: Interleukin-1 receptor antagonist anakinraCategories: Interleukin-1 Receptor AntagonistTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalSecond that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. … Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent
Synonyms: T-DM1Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFosaprepitant
go.drugbank.com/drugs/DB06717ApprovedInvestigationalFosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant.
Categories: Substance P/Neurokinin-1 Receptor Antagonist, Neurokinin 1 AntagonistsProducts: APRITANT IV® 150 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE, FOSAPRANT 150 MG İ.V. İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADETMitoxantrone
go.drugbank.com/drugs/DB01204ApprovedInvestigationalAn anthracenedione-derived antineoplastic agent.
Synonyms: 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinoneCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic IndexSorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigationalSorafenib is a bi-aryl urea and an oral multikinase inhibitor. … [A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma
Synonyms: N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index